These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21370275)

  • 1. Rasagiline-induced serotonin syndrome.
    Fernandes C; Reddy P; Kessel B
    Mov Disord; 2011 Mar; 26(4):766-7. PubMed ID: 21370275
    [No Abstract]   [Full Text] [Related]  

  • 2. Linezolid and Rasagiline - A culprit for serotonin syndrome.
    Hisham M; Sivakumar MN; Nandakumar V; Lakshmikanthcharan S
    Indian J Pharmacol; 2016; 48(1):91-2. PubMed ID: 26997732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of paroxetine and rasagiline induces serotonin syndrome in a parkinsonian patient.
    Hébant B; Guillaume M; Desbordes M; Gaillon G; Maltête D; Lefaucheur R
    Rev Neurol (Paris); 2016 Dec; 172(12):788-789. PubMed ID: 27838092
    [No Abstract]   [Full Text] [Related]  

  • 4. Rasagiline-induced spontaneous ejaculation.
    Chuang RS; Lang AE
    Mov Disord; 2009 Oct; 24(14):2160-1. PubMed ID: 19735087
    [No Abstract]   [Full Text] [Related]  

  • 5. Rasagiline as a therapy for Parkinson's disease (PD).
    Hermanowicz N
    Am J Geriatr Pharmacother; 2007 Jun; 5(2):174-5; author reply 175-6. PubMed ID: 17719520
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety of rasagiline in elderly patients with Parkinson disease.
    Goetz CG; Schwid SR; Eberly SW; Oakes D; Shoulson I;
    Neurology; 2006 May; 66(9):1427-9. PubMed ID: 16682679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Rasagiline. A new monoamine oxidase b inhibitor for Parkinson treatment].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2005 Jul; 28(7):224-7. PubMed ID: 16038119
    [No Abstract]   [Full Text] [Related]  

  • 8. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rasagiline. Parkinson's disease: a simple me-too.
    Prescrire Int; 2006 Dec; 15(86):220. PubMed ID: 17167927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group
    Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent Impulse Control Disorder Associated with Rasagiline Treatment of Parkinson's Disease.
    Levy A; Lang AE
    Can J Neurol Sci; 2017 Jul; 44(4):447-448. PubMed ID: 28767029
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
    deMarcaida JA; Schwid SR; White WB; Blindauer K; Fahn S; Kieburtz K; Stern M; Shoulson I; ;
    Mov Disord; 2006 Oct; 21(10):1716-21. PubMed ID: 16856145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rasagiline-induced severe recurrent hypoglycemia in a young woman without diabetes: a case report.
    Ibrahim FA; Rashid F; Hussain AA; Alawadi F; Bashier A
    J Med Case Rep; 2017 Feb; 11(1):29. PubMed ID: 28148284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rasagiline. Teva Pharmaceutical.
    Kupsch A
    Curr Opin Investig Drugs; 2002 May; 3(5):794-7. PubMed ID: 12090555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO).
    Panisset M; Chen JJ; Rhyee SH; Conner J; Mathena J;
    Pharmacotherapy; 2014 Dec; 34(12):1250-8. PubMed ID: 25314256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New drug treatment for Parkinson's disease.
    FDA Consum; 2006; 40(4):7. PubMed ID: 17245831
    [No Abstract]   [Full Text] [Related]  

  • 18. MAO-B inhibitor know-how: back to the pharm.
    Lewitt PA
    Neurology; 2009 Apr; 72(15):1352-7. PubMed ID: 19365057
    [No Abstract]   [Full Text] [Related]  

  • 19. Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline.
    Speiser Z; Fine T; Litinetsky L; Eliash S; Blaugrund E; Cohen S
    J Neural Transm (Vienna); 2008; 115(1):107-16. PubMed ID: 17823767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ziprasidone, monoamine oxidase inhibitors, and the serotonin syndrome.
    Rim CL; Gitlin MJ
    J Clin Psychopharmacol; 2010 Aug; 30(4):470-1. PubMed ID: 20631570
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.